Myofascial Pain Syndrome Withdrawn Phase 2 Trials for Capsaicin (DB06774)

Also known as: Myofacial Pain / Myofascial Trigger Point Pain (MTrP) / Myofascial Pain Dysfunction Syndrome / Trigger Point Pain, Myofascial / Myofascial Trigger Point Pain / Myofascial Pain Syndromes / Pain, Myofacial / Pain Syndrome Myofascial / Myofascial Pain / Fibromyalgia / Myalgia / Myofascial pain syndrome (disorder) / Fibromyalgia -RETIRED- / Fibromyalgia [Ambiguous] / Fibrositis / Fibromyositis (disorder) / Muscular rheumatism / Rheumatism &/or fibrositis: [NOS] / Fibrositis (disorder) / Temporomandibular joint-pain-dysfunction syndrome (disorder) / Fibromyositis NOS (disorder) / Fibromyositis / Muscular rheumatism (disorder) / Fibrositis unspecified (disorder) / Fibromyalgia syndrome / (Nonarticular rheumatism NOS) or (panniculitis) / Nonarticular rheumatism NOS (disorder) / Non-articular rheumatism (disorder) / Myofascial pain (finding) / Rheumatism (disorder) / Soft tissue rheumatism

IndicationStatusPhase
DBCOND0042349 (Myofascial Pain Syndrome)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00795106Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck PainTreatment